Ellen M. Lintal is the CFO & Chief Accounting Officer at AIM ImmunoTech Inc.
As the CFO & Chief Accounting Officer of AIM ImmunoTech Inc, the total compensation of Ms Lintal at AIM ImmunoTech Inc is $177,325. There are 7 executives at AIM ImmunoTech Inc getting paid more, with William Mitchell having the highest compensation of $1,696,680.
Ms Lintal is 61, she's been the CFO & Chief Accounting Officer of AIM ImmunoTech Inc since . There are 13 older and 1 younger executives at AIM ImmunoTech Inc. The oldest executive at AIM ImmunoTech Inc is William Mitchell, 81, who is the Chairman of the Board.
Ellen's mailing address filed with the SEC is 2117 SW HWY 484, , OCALA, FL, 34473.
Over the last 20 years, insiders at AIM ImmunoTech Inc have traded over $15,026,013 worth of AIM ImmunoTech Inc stock and bought 898,126 units worth $656,210 . The most active insiders traders include Thomas K Equels, J Mervyn Nabors, and Commercial Bank First. On average, AIM ImmunoTech Inc executives and independent directors trade stock every 125 days with the average trade being worth of $16,943. The most recent stock trade was executed by Thomas K Equels on 6 May 2024, trading 61,729 units of AIM stock currently worth $25,309.
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
AIM ImmunoTech Inc executives and other stock owners filed with the SEC include: